- The Mayo Clinic has closed the trial of Geron's (GERN) Imetelstat treatment to new patients after 14 months, although those who are already in the program will continue to receive therapy.
- The study is evaluating Imetelstat in patients with myelofibrosis and other myeloid malignancies.
- Geron believes that 79 patients were enrolled in the trial but that 20 have dropped out.
- Based on preliminary data from the study, Geron intends to start another Phase II trial in H1.
- Shares are -12.1%; Adam Feuerstein asks on Twitter whether people are "bothered by the 20 patients who dropped out of study?" (8-K)
From other sites
at CNBC.com (Nov 14, 2014)
at CNBC.com (Nov 3, 2014)
at CNBC.com (Aug 13, 2014)
at CNBC.com (Jun 12, 2014)
at CNBC.com (Dec 20, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs